Susanne Caspar – CEO, Linnea
Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has…
Santen is a leading multinational company that specializes in ophthalmology. President and Head for Europe, Middle East and Africa (EMEA) Luis Iglesias highlights the company’s recent transformation through partnerships across…
Swiss-headquartered ADIENNE has made recent headlines after being announced as the first European company to manufacture Russia’s Sputnik V COVID-19 vaccine. President and Founder Antonio Francesco Di Naro explains how…
In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production…
Georg Boonen, CEO of Switzerland’s leading phytopharmaceutical player Max Zeller, discusses the company’s expanded market position at home and abroad, how COVID-19 and a reconsideration of preventive healthcare could be…
Animal testing for medicinal purposes is back under the spotlight in Switzerland after a petition against the practice filed in Bern managed to generate tens of thousands of signatures. Even…
Vincent Gruntz looks at the market dynamics for oncology in Switzerland, where an increasingly cost-conscious approach is being taken to reimbursement and pricing, his experience of bringing CAR-T therapies to…
In February 2020, US giant MSD announced the launch of a new site in Zurich specialising in R&D, data management, and commercialisation, foregrounding the company’s commitment to Switzerland. MSD employs…
Biogen Switzerland’s Dr med Katharina Gasser outlines how her affiliate navigated the COVID-19 pandemic from an organisational and communication perspective, the increasing importance being given to mental health by the…
Michael Altorfer, CEO of the Swiss Biotech Association, a membership organisation representing the interests of the Swiss biotech industry, discusses the evolution of the biotech sector in Switzerland, how the…
Antonella Santuccione Chadha*, Head of Stakeholder Engagement for Alzheimer’s disease at Biogen and co-founder and CEO of the Women’s Brain Project, dives into the non-profit organization’s role in rethinking the…
In a recent conversation with PharmaBoardroom, Michael Sidler of Redalpine Venture Partners, a venture capital (VC) firm aiming to support founders and start-ups in Europe, highlighted how the European VC…
See our Cookie Privacy Policy Here
